The HTRA1 Knockout TE1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the TE1 human esophageal squamous cell carcinoma cell line. This product features targeted disruption of the HTRA1 gene via CRISPR/Cas9-mediated gene editing, resulting in a heterogeneous population of cells with loss-of-function mutations at the HTRA1 locus. The polyclonal format offers a biologically relevant pool of knockout cells, minimizing clonal artifacts and enabling robust assessment of HTRA1 function in a cancer-relevant context. This model is suitable for a wide range of assays investigating tumor suppression, apoptosis, and TGF-?? signaling.
The TE1 cell line is a well-established model of human esophageal squamous cell carcinoma, derived from a primary tumor. As a cancerous epithelial cell line, TE1 retains key characteristics of malignant esophageal cells, including deregulated growth and survival pathways. This background provides a clinically relevant platform to study the molecular mechanisms driving esophageal squamous cell carcinoma, particularly those involving the TGF-?? signaling axis and tumor-suppressive serine proteases. TE1 cells express functional components of the TGF-?? pathway, making them ideal for dissecting the impact of HTRA1 loss on signal transduction and cellular behavior.
HTRA1 is a serine protease that functions as a tumor suppressor by cleaving and inactivating TGF-??1 ligands, thereby inhibiting TGF-?? signaling. It is a key negative regulator of pathways mediated by the TGFBR1/TGFBR2 receptor complex and downstream SMAD2/SMAD3/SMAD4 transcription factors. Upstream, HTRA1 expression is regulated by TGF-??1 itself, DNMT1-mediated promoter methylation, and the tumor suppressor p53. Downstream targets of HTRA1 proteolytic activity include fibronectin, an extracellular matrix component, and XIAP, an inhibitor of apoptosis whose degradation by HTRA1 promotes programmed cell death. Additionally, HTRA1 interacts with and modulates the bioavailability of SERPINE1 (PAI-1) and proteoglycans, further impacting extracellular remodeling. In the TE1 esophageal cancer model, HTRA1 loss disrupts these regulatory networks, enhancing TGF-?? pathway activity and promoting a pro-survival phenotype.
In the TE1 cellular context, knockout of HTRA1 removes a critical brake on TGF-?? signaling and apoptosis regulation. The mechanistic consequence is heightened TGF-??1-driven SMAD-dependent transcription, increased expression of pro-tumorigenic target genes, and reduced apoptosis due to stabilized XIAP levels. This makes the HTRA1 knockout TE1 polyclonal cells a powerful tool for investigating the loss of tumor suppressor functions that are frequently observed in esophageal squamous cell carcinoma. Researchers can use this model to probe how epigenetic silencing or mutational inactivation of HTRA1 contributes to disease progression and to test restoration strategies aimed at reactivating endogenous tumor suppression.
This polyclonal knockout product is designed for diverse experimental applications, including screening for epigenetic modulators of HTRA1 expression, evaluating the role of extracellular matrix remodeling in cancer invasion, and validating HTRA1 as a biomarker for therapeutic response. Representative assays include quantitative RT-qPCR and western blotting to assess gene and protein expression, TGF-?? signaling reporter assays to monitor pathway activity, apoptosis and colony formation assays to measure cell survival, and migration/invasion assays to study metastatic potential. Co-immunoprecipitation experiments can be employed to examine HTRA1??s interactions with TGFBR2 or fibronectin. For additional technical details or ordering information, please contact Ascent Research.
